Literature DB >> 19797432

Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients.

Michael T Compton1, Mary E Kelley, Claire E Ramsay, Makenya Pringle, Sandra M Goulding, Michelle L Esterberg, Tarianna Stewart, Elaine F Walker.   

Abstract

OBJECTIVE: Several reports suggest that cannabis use is associated with an earlier age at onset of psychosis, although not all studies have operationalized cannabis use as occurring prior to onset of symptoms. This study addressed whether pre-onset cannabis use, alcohol use, and tobacco use are associated with an earlier age at onset of prodromal and psychotic symptoms. Effects of the progression of frequency of use were examined through time-dependent covariates in survival analyses.
METHOD: First-episode patients (N=109) hospitalized in three public-sector inpatient psychiatric units underwent in-depth cross-sectional retrospective assessments. Prior substance use and ages at onset of prodromal and psychotic symptoms were determined by standardized methods, and analyses were conducted using Cox regression modeling.
RESULTS: Whereas classifying participants according to maximum frequency of use prior to onset (none, ever, weekly, or daily) revealed no significant effects of cannabis or tobacco use on risk of onset, analysis of change in frequency of use prior to onset indicated that progression to daily cannabis and tobacco use was associated with an increased risk of onset of psychotic symptoms. Similar or even stronger effects were observed when onset of illness or prodromal symptoms was the outcome. A gender-by-daily-cannabis-use interaction was observed; progression to daily use resulted in a much larger increased relative risk of onset of psychosis in females than in males.
CONCLUSIONS: Pre-onset cannabis use may hasten the onset of psychotic as well as prodromal symptoms. Age at onset is a key prognostic factor in schizophrenia, and discovering modifiable predictors of age at onset is crucial.

Entities:  

Mesh:

Year:  2009        PMID: 19797432      PMCID: PMC3662470          DOI: 10.1176/appi.ajp.2009.09030311

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  49 in total

1.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

2.  Substance abuse and the onset of schizophrenia.

Authors:  M Hambrecht; H Häfner
Journal:  Biol Psychiatry       Date:  1996-12-01       Impact factor: 13.382

3.  Course of substance misuse and daily tobacco use in first-episode psychosis.

Authors:  Darryl Wade; Susy Harrigan; Jane Edwards; Philip M Burgess; Greg Whelan; Patrick D McGorry
Journal:  Schizophr Res       Date:  2005-11-17       Impact factor: 4.939

Review 4.  Pharmacology and effects of cannabis: a brief review.

Authors:  C H Ashton
Journal:  Br J Psychiatry       Date:  2001-02       Impact factor: 9.319

5.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

6.  Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients.

Authors:  J Rabinowitz; E J Bromet; J Lavelle; G Carlson; B Kovasznay; J E Schwartz
Journal:  Psychol Med       Date:  1998-11       Impact factor: 7.723

Review 7.  Cannabis and the brain.

Authors:  Leslie Iversen
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

9.  Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study.

Authors:  I Harrison; E M Joyce; S H Mutsatsa; S B Hutton; V Huddy; M Kapasi; T R E Barnes
Journal:  Psychol Med       Date:  2007-05-29       Impact factor: 7.723

10.  Endocannabinoid signalling in the blood of patients with schizophrenia.

Authors:  Nicola De Marchi; Luciano De Petrocellis; Pierangelo Orlando; Fabiana Daniele; Filomena Fezza; Vincenzo Di Marzo
Journal:  Lipids Health Dis       Date:  2003-08-19       Impact factor: 3.876

View more
  59 in total

1.  A comparison of correlates of suicidal ideation prior to initial hospitalization for first-episode psychosis with prior research on correlates of suicide attempts prior to initial treatment seeking.

Authors:  Peggy Flanagan; Michael T Compton
Journal:  Early Interv Psychiatry       Date:  2011-12-13       Impact factor: 2.732

Review 2.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

3.  Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis.

Authors:  Juan A Galvez-Buccollini; Ashley C Proal; Veronica Tomaselli; Melissa Trachtenberg; Cristinel Coconcea; Jinsoo Chun; Theo Manschreck; Jerry Fleming; Lynn E Delisi
Journal:  Schizophr Res       Date:  2012-06-21       Impact factor: 4.939

4.  Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset Schizophrenia.

Authors:  Daniel J Coletti; Mary Brunette; Majnu John; John M Kane; Anil K Malhotra; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2015-08-27       Impact factor: 9.306

5.  Illicit drug use in heavy smokers with and without schizophrenia.

Authors:  Kristen M Mackowick; Stephen J Heishman; Heidi J Wehring; Fang Liu; Robert P McMahon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-14       Impact factor: 4.939

6.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

7.  Persistent cannabis use among young adults with early psychosis receiving coordinated specialty care in the United States.

Authors:  Leslie Marino; Jennifer Scodes; Talia Richkin; Jean-Marie Alves-Bradford; Ilana Nossel; Melanie Wall; Lisa Dixon
Journal:  Schizophr Res       Date:  2020-05-28       Impact factor: 4.939

8.  Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Glen P Davis; Michael T Compton; Shuai Wang; Frances R Levin; Carlos Blanco
Journal:  Schizophr Res       Date:  2013-11-05       Impact factor: 4.939

9.  Subclinical psychosis syndromes in the general population: results from a large-scale epidemiological survey among residents of the canton of Zurich, Switzerland.

Authors:  W Rössler; V Ajdacic-Gross; H Haker; S Rodgers; M Müller; M P Hengartner
Journal:  Epidemiol Psychiatr Sci       Date:  2013-11-26       Impact factor: 6.892

10.  Demographic and socioenvironmental predictors of premorbid marijuana use among patients with first-episode psychosis.

Authors:  Luca Pauselli; Michael L Birnbaum; Beatriz Paulina Vázquez Jaime; Enrico Paolini; Mary E Kelley; Beth Broussard; Michael T Compton
Journal:  Schizophr Res       Date:  2018-02-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.